Madrigal Pharmaceuticals Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
915
- Stock Symbol
-
MDGL
- Investments
-
3
- Share Price
-
$427.39
- (As of Friday Closing)
Madrigal Pharmaceuticals General Information
Description
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Contact Information
Website
www.madrigalpharma.comCorporate Office
- 200 Barr Harbor Drive
- Suite 200
- West Conshohocken, PA 19428
- United States
Corporate Office
- 200 Barr Harbor Drive
- Suite 200
- West Conshohocken, PA 19428
- United States
Madrigal Pharmaceuticals Timeline
Madrigal Pharmaceuticals Stock Performance
As of 13-Nov-2026, Madrigal Pharmaceuticals’s stock price is $427.39. Its current market cap is $9.9B with 23.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $427.39 | $425.21 | $353.54 - $615.00 | $9.9B | 23.2M | 354K | -$5.89 |
Madrigal Pharmaceuticals Financials Summary
As of 30-Sep-2026, Madrigal Pharmaceuticals has a trailing 12-month revenue of $1.43B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,152,553 | 12,462,421 | 5,850,551 | 4,452,265 |
| Revenue | 1,427,940 | 958,403 | 180,133 | 0 |
| EBITDA | (154,833) | (301,833) | (496,779) | (379,969) |
| Net Income | (155,463) | (288,284) | (465,892) | (373,630) |
| Total Assets | 1,434,389 | 1,259,589 | 1,042,247 | 640,547 |
| Total Debt | 354,217 | 347,630 | 119,570 | 117,193 |
Madrigal Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Madrigal Pharmaceuticals Comparisons
Industry
Financing
Details
Madrigal Pharmaceuticals Competitors (67)
One of Madrigal Pharmaceuticals’s 67 competitors is Harmony Biosciences Holdings, a Formerly VC-backed company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Hepion Pharmaceuticals | Corporation | Edison, NJ | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH | ||||
| DiaMedica Therapeutics | Formerly VC-backed | Minneapolis, MN |
Madrigal Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Madrigal Pharmaceuticals Patents
Madrigal Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107045-A1 | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension | Pending | 12-Nov-2024 | ||
| AU-2025217722-A1 | Methods for treating a fatty liver disease | Pending | 06-Feb-2024 | ||
| EP-4658275-A1 | Methods for treating a fatty liver disease | Pending | 06-Feb-2024 | ||
| EP-4803100-A2 | Methods for treating a fatty liver disease | Pending | 06-Feb-2024 | ||
| US-12377104-B1 | Methods for treating a fatty liver disease | Active | 06-Feb-2024 | A61P1/16 |
Madrigal Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Madrigal Pharmaceuticals Investments & Acquisitions (3)
Madrigal Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Pfizer (Global License of Ervogastat). The deal was made on 09-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pfizer (Global License of Ervogastat) | 09-Jan-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Synta Pharmaceuticals | 22-Jul-2016 | Merger/Acquisition | Pharmaceuticals | ||
| Via Pharmaceuticals | 30-Sep-2011 | Merger/Acquisition | Biotechnology |
Madrigal Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
31.03 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Madrigal Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Canticle Pharmaceuticals | Conshohocken, PA | 2011 |
Madrigal Pharmaceuticals FAQs
-
When was Madrigal Pharmaceuticals founded?
Madrigal Pharmaceuticals was founded in 2008.
-
Where is Madrigal Pharmaceuticals headquartered?
Madrigal Pharmaceuticals is headquartered in West Conshohocken, PA.
-
What is the size of Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has 915 total employees.
-
What industry is Madrigal Pharmaceuticals in?
Madrigal Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Madrigal Pharmaceuticals a private or public company?
Madrigal Pharmaceuticals is a Public company.
-
What is Madrigal Pharmaceuticals’s stock symbol?
The ticker symbol for Madrigal Pharmaceuticals is MDGL.
-
What is the current stock price of Madrigal Pharmaceuticals?
As of 13-Nov-2026 the stock price of Madrigal Pharmaceuticals is $427.39.
-
What is the current market cap of Madrigal Pharmaceuticals?
The current market capitalization of Madrigal Pharmaceuticals is $9.9B.
-
What is Madrigal Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Madrigal Pharmaceuticals is $1.43B.
-
Who are Madrigal Pharmaceuticals’s competitors?
Harmony Biosciences Holdings, Hepion Pharmaceuticals, Intercept Pharmaceuticals, Abeona Therapeutics, and DiaMedica Therapeutics are some of the 67 competitors of Madrigal Pharmaceuticals.
-
What is Madrigal Pharmaceuticals’s annual earnings per share (EPS)?
Madrigal Pharmaceuticals’s EPS for 12 months was -$5.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
